BCG Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Freeze-dried BCG Vaccine, Liquid BCG Vaccine), By Application (Tuberculosis (TB) Prevention, Bladder Cancer Treatment, Leprosy Prevention) and Regional Forecast to 2033

BCG VACCINE MARKET OVERVIEW

BCG Vaccine Market Size was estimated at USD 394.63 million in 2024 and it is expected to grow from USD 416.73 million in 2025 to USD 464.71 million by 2033. The Market CAGR (growth rate) is expected to be around 5.6% during the forecast period (2025 - 2033).

The BCG (Bacillus Calmette-Guérin) vaccine market works mainly with the demand for TB prevention globally and more so in high-risk locations. The major use of BCG vaccines is the most commonly used vaccines for TB, which is most administered to infants of endemic regions. Other influences to the market are through its mode in the cure of bladder cancer and its preventive measure for leprosy. Its cost-effectiveness and long immunity remain as reasons why it is continued to be used.

• • 

    Request a Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The BCG Vaccine Market size was USD 394.63 Million in 2024, is projected to grow to USD 412.73 Million by 2025 and exceed USD 464.71 Million by 2033, with a CAGR of 5.6%.

• Key Market Driver: TB remains a global health threat—over 10.6 million people fell ill with it in 2022 alone, which is why governments continue to fund universal immunization programs using BCG.

• Major Market Restraint: WHO data from 2022 showed that nearly 3 million children missed routine immunizations due to pandemic disruptions—a tough setback for vaccine distribution efforts, especially in low-income nations.

• Emerging Trends: Researchers are exploring BCG’s potential beyond TB—some early trials have shown a 30% reduction in infection rates for respiratory diseases among elderly patients post-BCG vaccination.

• Regional Leadership: Asia-Pacific leads the charge, with India alone administering over 25 million BCG doses annually, largely due to its birth cohort size and national TB control program.

• Competitive Landscape: The space isn’t overly crowded—around 8 major manufacturers control bulk of the market, including Serum Institute, Merck, and Japan BCG Laboratory, creating high entry barriers.

• Market Segmentation: Pediatric use dominates the market, accounting for nearly 88% of administered doses in 2023, thanks to mandatory immunization policies in over 100 countries.

• Recent Development: In early 2024, a Phase III trial was launched in Europe to study BCG’s role in bladder cancer therapy, enrolling over 1,200 participants across 9 countries.

COVID-19 IMPACT

"BCG Vaccine Market Had a Negative Effect Due To Supply Chain Disruption During COVID-19 Pandemic"

The Global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic caused disruption in vaccination programs and health care supply chains across many parts of the world, thereby negatively impacting the BCG vaccine market. Lockdowns and restrictions further delayed schedules for vaccinations, mainly in low- and middle-income countries where TB is highly prevalent. A lot of attention and resources were directed towards ensuring COVID-19 vaccination, which left routine immunizations, including the BCG vaccine, in neglect and with resultant lower coverage.

LATEST TREND

"Growing Interest In Its Potential Role In Cancer Immunotherapy To Drive Market Growth"

A very notable recent trend in the BCG vaccine market is its gaining interest in the context of its probable role in cancer immunotherapy in the form of bladder cancer. Scientists have been exploring intravesical BCG vaccine treatment as an immune system enhancer against bladder cancer cells and have resulted in its increased usage beyond the utilization of it as an anti-tuberculosis vaccine. Further, the advances in the stabilization of vaccine formulations are making it more feasible to distribute, especially the freeze-dried BCG vaccines, even where refrigeration capabilities are not readily available.

BCG VACCINE MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Freeze-dried BCG Vaccine, Liquid BCG Vaccine

• Lyophilized BCG Vaccine: This vaccine is mainly used to immunize against tuberculosis (TB) and has a more extended shelf life. Freezed-dried BCG vaccines are also more stable as they are normally used in areas where there may not be access to refrigeration. They are reconstituted with a diluent before injection and are commonly used worldwide in global TB vaccination programs.

• Liquid BCG Vaccine: Liquid formulations, the liquid BCG vaccines are ready-to-use formulations. The shelf life is lower than the freeze-dried one, and the formulation is kept in a controlled environment. They are mostly applied in hospitals and other medical setups where use is needed instantly.

By Application

Based on application, the global market can be categorized into Tuberculosis (TB) Prevention, Bladder Cancer Treatment, Leprosy Prevention

• Primary Prevention: Tuberculosis TB prevention can be achieved through the BCG vaccine, mainly used for tuberculosis prevention in countries with high levels of the disease. It is administered to infants and children to shield them from the disease, which may cause severe lung and systemic infections.

• Bladder Cancer Treatment: The BCG vaccine not only is the vaccination against TB but is also applied in the treatment of superficial bladder cancer. Intravesical administration of the vaccine helps provoke the immune system and prevents recurrence of bladder tumors.

• Use of BCG as a Prophylactic: Treatment against Leprosy Leprosy is practiced in some countries as the use of BCG as a prophylactic treatment against leprosy. The disease remains endemic in that area, and the vaccine works as a form of immunity against mycobacterial diseases, thus preventing its transmission.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions. 

Driving Factors

"Increasing TB Incidence to Boost the Market"

There is a noticeable boost in the BCG Vaccine Market growth. The growing incidence of tuberculosis (TB) globally drives the BCG vaccine market. TB continues to pose a major global health threat, especially in developing countries, where healthcare is not adequately accessible. BCG vaccines are crucial for the prevention of TB. As more cases of TB are recorded, vaccination programs and BCG vaccines gain demand, pushing the market forward.

"Growing Cancer Immunotherapy Applications to Expand the Market"

The next significant driver is the fact that BCG vaccine is increasingly being used in the treatment of bladder cancer. Increasingly, intravesical administration of BCG vaccines is emerging as an effective immunotherapy for superficial bladder cancer, giving hope to patients in search of an alternative treatment to surgery. This rising demand is causing immense demand for BCG vaccines in the healthcare industry specifically focused on oncology.

Restraining Factor

"Supply Chain Disruptions to Potentially Impede Market Growth"

Supply chain disruption as made worse by COVID-19 is the biggest challenge facing the BCG vaccine market. Among the factors that have contributed to the unavailability of the vaccines are delays in manufacturing, storage, and transport. Given these facts, the supply of timely delivery of vaccine supply to help implement immunisation programs using BCG vaccines will be affected as immunization programs have been disrupted globally.

Opportunity

"Vaccine Innovation & Stability Improvements To Create Opportunity For The Product In The Market"

Other areas of market growth relate to innovations in vaccine formulations. Freeze-dried BCG vaccines, for example, have a higher shelf life and better stability; hence, they do not require refrigeration infrastructure in most locations across the world. Improved stability of vaccines will maximize access and facilitate increased vaccination coverage.

Challenge

"Vaccine Hesitancy & Awareness Challenges Could Be A Potential Challenge For Consumers"

One of the biggest barriers in increasing BCG vaccine uptake is vaccine hesitancy. Most of the time, incorrect assumptions are made regarding the safety or efficacy of vaccines - especially in settings where information on TB is limited. Such knowledge needs to be obtained by educating the public and health care providers about the need for BCG vaccination.

• • 

    Request a Free sampleto learn more about this report.

•  

BCG VACCINE MARKET REGIONAL INSIGHTS

North America

The North America region has a growing United States BCG Vaccine Market. North America is the foremost market of BCG vaccine, mainly due to its developed health infrastructure and continuous emphasize on treatment for bladder cancer. The BCG vaccine is so widely used in immunizing the at risk group as well as in the treatment of bladder cancer; thereby it is an essential part of the programs of oncology and control of tuberculosis. Although the TB prevalence is minimal in the region, its cancer therapy market maintains high demand.

Asia-Pacific (India & China)

Asia-Pacific, especially India and China, is considered to be one of the main markets for the BCG vaccine market due to a huge burden of tuberculosis within its borders. Expansion of the coverage of national TB prevention programs with the BCG vaccine is integral for the control of the disease in highly populated areas.

Africa (Sub-Saharan Africa)

Sub-Saharan Africa continues to be a major focus area, and TB incidence is high. In low-resourced countries, targeting routine immunization for infants by vaccinating with the BCG also has an effect of diminishing the transmission rates of TB.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

Global pharmaceutical companies, biotechnology companies, and specialized vaccine manufacturers are major industrial participants in the BCG vaccine market. These companies strive to manufacture and distribute BCG vaccines for the prevention of tuberculosis as well as for cancer immunotherapy. They continue to increase their research and development capabilities with the objective of manufacturing more advanced vaccine formulations that offer better stability, a longer shelf life, and greater effectiveness.

List of Top BCG Vaccine Market Companies

• Sanofi Pasteur (France)
• Merck & Co., Inc. (U.S.)
• Baxter International Inc. (U.S.)
• Becton, Dickinson and Company (BD) (U.S.)
• China National Pharmaceutical Group (China)
• GlaxoSmithKline (GSK) (UK)
• Cipla Limited (India)
• Roche (Switzerland)

KEY INDUSTRY DEVELOPMENT

July 2021: A notable industrial development in the BCG vaccine market came in when a leading international organization of health declared that it had successfully run pilot programs on enhanced stability formulations for the BCG vaccine in July 2021. The new versions, including freeze-dried ones, are assumed to make better use of the shelf life of the vaccine and to make more safe deliveries even in tricky and distant parts of the world that lack good refrigeration facilities. With this new development, the BCG vaccines will become more accessible and effective in the prevention of tuberculosis across low-resource regions.

REPORT COVERAGE

This report contains an analysis of market trends, growth drivers, and challenges of the BCG vaccine. Complete segmentation is provided as either freeze-dried or liquid formulation and application: prevention of tuberculosis, treatment of bladder cancer, and prevention of leprosy. Regional markets are analyzed with emphasis on North America, Asia-Pacific, and Sub-Saharan Africa regions, key demand drivers, and regional variations. It encompasses the competitive landscape, key industrial players, and recent advances, including formulations of new vaccines.